| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential | Frank Vinluan | 02/12/20 | San Diego |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More | Sarah de Crescenzo | 12/06/19 | National |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| BeiGene Puts Up $10M to Use Ambrx’s Drug Development Technology | Sarah de Crescenzo | 03/07/19 | San Diego |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| Bio Roundup: Trump’s Budget, Biogen’s AD Reveal, Hugin’s Run & More | Alex Lash | 02/16/18 | National |
| Astellas Buys Stem Cell Gene-Editing Firm Universal Cells for $102.5M | Corie Lok | 02/14/18 | Seattle |
| Starting a Medtech Company? Try Skipping Venture Capital, VCs Say | David Holley | 02/14/17 | Texas |
| Amylyx Nabs $5M to Take Aim at Nerve Cell Death in ALS Patients | David Holley | 08/22/16 | Boston |
| Cytokinetics Gets $95M in First ALS Deal, Needs Results For More | David Holley | 07/27/16 | San Francisco |
| East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More | Ben Fidler | 08/15/14 | Boston |
| San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs | Bruce V. Bigelow | 04/08/13 | San Diego |
| East Coast Life Sciences Roundup: Optimer, Bind, Pfizer, and More | Bernadette Tansey | 04/05/13 | Boston |
| San Diego Life Sciences Roundup: Qualcomm, Amylin, Organovo & More | Bruce V. Bigelow | 04/04/13 | San Diego |
| Optimer Shares Soar Amid Reports of Buyout Interest | Bruce V. Bigelow | 04/02/13 | San Diego |
